脓毒症患者抗氧化水平对预后的影响

注册号:

Registration number:

ChiCTR-POC-16009704 

最近更新日期:

Date of Last Refreshed on:

2016-11-01 21:53:13 

注册时间:

Date of Registration:

2016-11-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

脓毒症患者抗氧化水平对预后的影响

Public title:

Influence of antioxidant level on prognosis in sepsis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

严重脓毒症患者抗氧化水平对预后的影响

Scientific title:

Influence of antioxidant level on prognosis in severe sepsis

研究课题代号(代码):

Study subject ID:

Y201016891

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

许俞露 

研究负责人:

方雪玲 

Applicant:

Xu Yulu 

Study leader:

Fang Xueling 

申请注册联系人电话:

Applicant telephone:

+86 18768197252

研究负责人电话:

Study leader's
telephone:

+86 13588867114

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xuyulu2010@126.com

研究负责人电子邮件:

Study leader's E-mail:

13588867114@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市江干区凯旋街道浙江大学华家池校区

研究负责人通讯地址:

浙江省杭州市庆春路79号

Applicant address:

Huajiachi Campus, Zhejiang University, Kaixuan Street, Hangzhou, Zhejiang, China

Study leader's address:

79 Qingchun Road, Hangzhou, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院

Applicant's institution:

The College of Medicine, Zhejiang University

研究负责人所在单位:

浙江大学医院院附属第一医院

Affiliation of the Leader:

The First Affiliated Hosptial of College of Medicine, Zhejiang University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2016-453

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属第一医院医学伦理委员会

Name of the ethic committee:

Ethies Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University

伦理委员会批准日期:

Date of approved by ethic committee:

2016-10-19 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属第一医院

Primary sponsor:

The First Affiliated Hosptial of College of Medicine, Zhejiang University

研究实施负责(组长)单位地址:

浙江省杭州市庆春路79号

Primary sponsor's address:

79 Qingchun Road, Hangzhou, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学医学院附属第一医院

具体地址:

浙江省杭州市庆春路79号

Institution
hospital:

The First Affiliated Hosptial of College of Medicine,Zhejiang University.

Address:

79 Qingchun Road, Hangzhou, Zhejiang, China

经费或物资来源:

自筹

Source(s) of funding:

self-raised

研究疾病:

脓毒症  

Target disease:

Sepsis

研究疾病代码:

Target disease code:

研究类型:

预后研究

Study type:

Prognosis study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

寻找可以评估脓毒症预后的指标  

Objectives of Study:

to seek the predictors used to access prognosis of sepsis

药物成份或治疗方案详述:

无 

Description for medicine or protocol of treatment in detail:

None 

纳入标准:

Inclusion criteria

排除标准:

年龄小于18岁,慢性肝或肾功能不全,肿瘤化疗或放疗术后

Exclusion criteria:

Aged younger than 18, chronic hepatic or renal insufficiency, neoplasia receiving chemo or radiotherapy,
and immunodeficiency.

研究实施时间:

Study execute time:

From 2016-11-01 00:00:00 To 2017-10-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-11-01 00:00:00 To 2017-10-31 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

100

Group:

1

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学医学院附属第一医院 

单位级别:

三级甲等医院 

Institution
hospital:

The First Affiliated Hosptial of College of Medicine,Zhejiang University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

丙二醛

指标类型:

主要指标

Outcome:

Malonaldehyde

Type:

Primary indicator

测量时间点:

入ICU后第1天、第3天、第6天、第14天、第21天直到死亡或出ICU

测量方法:

Measure time point of outcome:

Within 24 hours (D1) and Day3,Day6,Day14,Day21 after ICU admission until dead or go out of ICU

Measure method:

指标中文名:

超氧化物歧化酶

指标类型:

主要指标

Outcome:

superoxide dismutase

Type:

Primary indicator

测量时间点:

入ICU第1天、第3天、第6天、第14天、第21天直到死亡或出ICU

测量方法:

Measure time point of outcome:

Within 24 hours (D1) and Day3,Day6,Day14,Day21 after ICU admission until dead or go out of ICU

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese clinical trial registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

原始数据采用Excel保存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel will be used to preserve data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2016-11-01 21:53:13